Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz is continuing its investigation of Alnylam Pharmaceuticals (ALNY) for possible federal securities law violations and is soliciting shareholders who lost money to contact the firm. The investigation stems from Alnylam's July 30, 2026 Q2 disclosure cutting full-year 2026 TTR product sales guidance by roughly $200 million, after which shares fell 28.31% to $205.48.
Key figures
- Share price drop
- $81.14
- Ttr guidance cut
- $200 million
- Close price jul30
- $205.48
- Share price drop pct
- 28.31%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.